PhaseV

Cambridge, Massachusetts, USA · ≈72 employees · phasevtrials.com

PhaseV is a Boston-based technology company founded in 2023 that specializes in optimizing clinical development for biopharma sponsors and contract research organizations (CROs) through an AI/ML-driven platform. The company aims to enhance the clinical trial industry by accelerating the delivery of new treatments to patients while improving efficiency and precision. The core of PhaseV's offering is its AI Conductor platform, which automates various stages of the clinical trial process, from protocol drafting to final report submission. This platform includes tools like the Trial Optimizer and advanced causal machine learning algorithms, which help refine trial endpoints and streamline operational workflows. PhaseV serves over 30 global pharmaceutical companies and CROs across more than 20 therapeutic areas, including oncology and neurology. The company operates on a B2B model, providing subscription-based SaaS and consulting services to its clients.

Research

Also: biotechnology research · clinical development decision support · heterogeneity treatment effects · ai trial optimization · ai in clinical trials · clinical trial monitoring · clinical trial heterogeneity analysis · biopharma cro · pharma ai platform · trial outcome prediction · adaptive trial optimization · causal disease graphs

Funding0

Every round, secondary, debt facility or acquisition involving PhaseV that Lounge tracks, newest first.

No rounds recorded yet.

Paid members see the full deals desk — every AI round and exit, filterable by type, sector and country, with investors and reported ARR, plus CSV exports. Developer membership is $9/mo.

See plans →Log in

PhaseV

Funding0

Key numbers

Also on Lounge

Similar companies